Analytical toxicology of emerging drugs of abuse

Therapeutic Drug Monitoring

Volumn 32, Issue 5, 2010, Pages 532-539

  Peters, Frank T ^a   Martinez Ramirez, Jorge A ^a,b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

amphetamines; analytical toxicology; cannabinoids; drugs of abuse; phenethylamines; piperazines; pyrrolidinophenones

Indexed keywords

AMPHETAMINE DERIVATIVE; CANNABINOID DERIVATIVE; ILLICIT DRUG; PHENETHYLAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE;

CHROMATOGRAPHY; DRUG ABUSE; DRUG DETERMINATION; DRUG SCREENING; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; REVIEW; SEPARATION TECHNIQUE; TOXICOLOGY;

AMPHETAMINES; CANNABINOIDS; DESIGNER DRUGS; FORENSIC TOXICOLOGY; HUMANS; PHENETHYLAMINES; PIPERAZINES; PYRROLIDINONES; STREET DRUGS; SUBSTANCE ABUSE DETECTION;

EID: 77957254699     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181f33411     Document Type: Review

References (75)

1. Maurer HH. Methods for GC-MS. In: Maurer HH, Pfleger K, Weber A, eds. Mass Spectral and GC Data of drugs, Poisons, Pesticides, Pollutants and Their Metabolites, part 1, 3rd ed.Weinheim:Wiley-VCH; 2007:4-32.
2. Maurer HH, Pfleger K, Weber AA, eds. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites, 4th rev ed. Weinheim: Wiley-VCH; 2007.
3. Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and the toxicological analysis of the new piperazine-like designer drug Nbenzylpiperazine in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;773:35-46. (Pubitemid 34518268)
4. Staack RF, Fritschi G, Maurer HH. New designer drug 1-(3- trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. J Mass Spectrom. 2003;38:971-981. (Pubitemid 37121814)
5. Staack RF, Maurer HH. Piperazine-derived designer drug 1-(3-chlorophenyl) piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in urine including analytical differentiation from its precursor drugs trazodone and nefazodone. J Anal Toxicol. 2003;27: 560-568.
6. Staack RF, Maurer HH. Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;798:333-342.
7. Staack RF, Maurer HH. New designer drug 1-(3,4-methylenedioxybenzyl) piperazine (MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom. 2004;39:255-261.
8. Theobald DS, Fehn S, Maurer HH. New designer drug 2,5-dimethoxy-4- propylthiophenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom. 2005;40:105-116.
9. Theobald DS, Staack RF, Puetz M, et al. New designer drug 2,5- dimethoxy-4-ethylthio-beta-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/ mass spectrometry. J Mass Spectrom. 2005;40:1157-1172.
10. Theobald DS, Putz M, Schneider E, et al. New designer drug 4-iodo-2,5- dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques. J Mass Spectrom. 2006;41:872-886.
11. Theobald DS, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy-beta-phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;842:76-90.
12. Theobald DS, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl-beta-phenethylamine (2C-D) in rat urine using gas chromatographic-mass spectrometric techniques. J Mass Spectrom. 2006;41:1509-1519.
13. Theobald DS, Fritschi G, Maurer HH. Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) in rat urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;846:374-377. (Pubitemid 46149509)
14. Ewald AH, Peters FT, Weise M, et al. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;824:123-131.
15. Staack RF, Fehn J, Maurer HH. New designer drug para- methoxymethamphetamine: Studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;789:27-41.
16. Meyer MR, Wilhelm J, Peters FT, et al. Beta-keto amphetamines: studies on the metabolism of the designer drug mephdrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem. 2010;397: 1225-1233.
17. Ewald AH, Fritschi G, Bork WR, et al. Designer drugs 2,5-dimethoxy-4- bromoamphetamine (DOB) and 2,5-dimethoxy-4-bromomethamphetamine (MDOB): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom. 2006;41:487-498. (Pubitemid 43668077)
18. Ewald AH, Fritschi G, Maurer HH. Designer drug 2,4,5- trimethoxyamphetamine (TMA-2): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom. 2006;41:1140-1148. (Pubitemid 44454167)
19. Ewald AH, Fritschi G, Maurer HH. Metabolism and toxicological detection of the designer drug 4-iodo-2,5-dimethoxy-amphetamine (DOI) in rat urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;857:170-174. (Pubitemid 47362858)
20. Ewald AH, Puetz M, Maurer HH. Designer drug 2,5-dimethoxy-4- methyl-amphetamine (DOM, STP): Involvement of the cytochrome P450 isoenzymes in formation of its main metabolite and detection of the latter in rat urine as proof of a drug intake using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;862: 252-256.
21. Ewald AH, Ehlers D, Maurer HH. Metabolism and toxicological detection of the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas chromatography-mass spectrometry. Anal Bioanal Chem. 2008; 390:1837-1842.
22. Balikova M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci Int. 2005;153:85-91.
23. Beyer J, Ehlers D, Maurer HH. Abuse of nutmeg (Myristica fragrans Houtt.): studies on the metabolism and the toxicological detection of its ingredients elemicin, myristicin and safrole in rat and human urine using gas chromatography/mass spectrometry. Ther Drug Monit. 2006;28: 568-575.
24. Bickeboeller-Friedrich J, Maurer HH. Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GCMS developed using rat liver microsomes. Ther Drug Monit. 2001;23:61-70.
25. Pichini S, Pujadas M, Marchei E, et al. Liquid chromatography- atmospheric pressure ionization electrospray mass spectrometry determination of hallucinogenic designer drugs in urine of consumers. J Pharm Biomed Anal. 2008;47:335-342.
26. Nordgren HK, Holmgren P, Liljeberg P, et al. Application of direct urine LC-MS-MS analysis for screening of novel substances in drug abusers. J Anal Toxicol. 2005;29:234-239.
27. Paul LD, Musshoff F. Richtilinie der GTFCh zur Qualitätssicherung bei forensisch-toxikologischen Untersuchungen. Toxichem Krimtech. 2009; 76:142-176.
28. Peters FT, Schaefer S, Staack RF, et al. Screening for and validated quantification of amphetamines and of amphetamine- and piperazinederived designer drugs in human blood plasma by gas chromatography/ mass spectrometry. J Mass Spectrom. 2003;38:659-676.
29. Habrdova V, Peters FT, Theobald DS, et al. Screening for and validated quantification of phenethylamine-type designer drugs and mescaline in human blood plasma by gas chromatography/mass spectrometry. J Mass Spectrom. 2005;40:785-795.
30. de Boer D, Bosman IJ, Hidvegi E, et al. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int. 2001;121:47-56.
31. Vorce SP, Holler JM, Levine B, et al. Detection of 1-benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-ESI-MS. J Anal Toxicol. 2008;32:444-450.
32. Elliott S, Smith C. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol. 2008;32:172-177.
33. Tsutsumi H, Katagi M, Miki A, et al. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)- piperazine (TFMPP) and their main metabolites in urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;819:315-322.
34. Tsutsumi H, Katagi M, Miki A, et al. Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in rats. Xenobiotica. 2005;35:107-116.
35. Tsutsumi H, Katagi M, Miki A, et al. Metabolism and the urinary excretion profile of the recently scheduled designer drug N-benzylpiperazine (BZP) in the rat. J Anal Toxicol. 2006;30:38-43.
36. Kovaleva J, Devuyst E, De Paepe P, et al. Acute chlorophenylpiperazine overdose: a case report and review of the literature. Ther Drug Monit. 2008;30:394-398.
37. Staack RF, Maurer HH. Studies on the metabolism and the toxicological analysis of the nootropic drug fipexide in rat urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;804:337-343.
38. Staack RF, Theobald DS, Maurer HH. Studies on the human metabolism and the toxicologic detection of the cough suppressant dropropizine in urine using gas chromatography-mass spectrometry. Ther Drug Monit. 2004;26:441-449.
39. de Boer D, Gijzels MJ, Bosman IJ, et al. More data about the new psychoactive drug 2C-B [Letter; comment]. J Anal Toxicol. 1999;23:227-228.
40. Apollonio LG, Whittall IR, Pianca DJ, et al. Matrix effect and cross-reactivity of select amphetamine-type substances, designer analogues, and putrefactive amines using the Bio-Quant direct ELISA presumptive assays for amphetamine and methamphetamine. J Anal Toxicol. 2007;31:208-213.
41. Chiu YC, Chou SH, Liu JT, et al. The bioactivity of 2,5-dimethoxy-4- ethylthiophenethylamine (2C-T-2) and its detection in rat urine by capillary electrophoresis combined with an on-line sample concentration technique. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;811: 127-133.
42. Boatto G, Nieddu M, Dessi G, et al. Determination of four thiophenethylamine designer drugs (2C-T-series) in human plasma by capillary electrophoresis with mass spectrometry detection. J Chromatogr A. 2007; 1159:198-202. (Pubitemid 47048237)
43. Curtis B, Kemp P, Harty L, et al. Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J Anal Toxicol. 2003;27:493-498.
44. Vorce SP, Sklerov JH. A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS. J Anal Toxicol. 2004; 28:407-410.
45. Kanamori T, Inoue H, Iwata Y, et al. In vivo metabolism of 4-bromo-2,5- dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites. J Anal Toxicol. 2002;26:61-66.
46. Kanamori T, Tsujikawa K, Ohmae Y, et al. Excretory profile of 4-bromo- 2,5-dimethoxy-phenethylamine (2C-B) in rat. J Health Sci. 2003;49:166-169.
47. Kanamori T, Kuwayama K, Tsujikawa K, et al. In vivo metabolism of 2,5- dimethoxy-4-propylthiophenethylamine in rat. Xenobiotica. 2007;37:679-692.
48. Andreasen MF, Telving R, Birkler RI, et al. A fatal poisoning involving Bromo-Dragonfly. Forensic Sci Int. 2009;183:91-96.
49. Nieddu M, Boatto G, Pirisi MA, et al. Multi-residue analysis of eight thioamphetamine designer drugs in human urine by liquid chromatography/ tandem mass spectrometry. Rapid Commun Mass Spectrom. 2009; 23:3051-3056.
50. Kraner JC, McCoy DJ, Evans MA, et al. Fatalities caused by the MDMArelated drug paramethoxyamphetamine (PMA). J Anal Toxicol. 2001;25: 645-648.
51. Loor R, Lingenfelter C,Wason PP, et al. Multiplex assay of amphetamine, methamphetamine, and ecstasy drug using CEDIA technology. J Anal Toxicol. 2002;26:267-273.
52. Elliott SP. Fatal poisoning with a new phenylethylamine: 4-methylthioamphetamine (4- MTA). J Anal Toxicol. 2000;24:85-89.
53. Zaitsu K, Katagi M, Kamata HT, et al. Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int. 2009;188:131-139.
54. Elliott SP. Analysis of 4-methylthioamphetamine in clinical specimens. Ann Clin Biochem. 2001;38:339-347.
55. Decaestecker T, De Letter E, Clauwaert K, et al. Fatal 4-MTA intoxication: development of a liquid chromatographic-tandem mass spectrometric assay for multiple matrices. J Anal Toxicol. 2001;25: 705-710.
56. Johansen SS, Hansen AC, Muller IB, et al. Three fatal cases of PMA and PMMA poisoning in Denmark. J Anal Toxicol. 2003;27:253-256.
57. Martin TL. Three cases of fatal paramethoxyamphetamine overdose. J Anal Toxicol. 2001;25:649-651.
58. Mortier KA, Dams R, Lambert WE, et al. Determination of paramethoxyamphetamine and other amphetamine-related designer drugs by liquid chromatography/sonic spray ionization mass spectrometry. Rapid Commun Mass Spectrom. 2002;16:865-870.
59. Becker J, Neis P, Rohrich J, et al. A fatal paramethoxymethamphetamine intoxication. Leg Med (Tokyo). 2003;5(Suppl 1):S138-S141.
60. Dams R, De Letter EA, Mortier KA, et al. Fatality due to combined use of the designer drugs MDMA and PMA: a distribution study. J Anal Toxicol. 2003;27:318-322.
61. Kudo K, Ishida T, Hara K, et al. Simultaneous determination of 13 amphetamine related drugs in human whole blood using an enhanced polymer column and gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;855:115-120.
62. Lin DL, Liu HC, Yin HL. Recent paramethoxymethamphetamine (PMMA) deaths in Taiwan. J Anal Toxicol. 2007;31:109-113.
63. Zaitsu K, Katagi M, Kamata T, et al. Determination of a newly encountered designer drug-p-methoxyethylamphetamine- and its metabolites in human urine and blood. Forensic Sci Int. 2008;177:77-84.
64. Kraemer T, Bickeboeller-Friedrich J, Maurer HH. On the metabolism of the amphetamine-derived antispasmodic drug mebeverine: gas chromatography- mass spectrometry studies on rat liver microsomes and on human urine. Drug Metab Dispos. 2000;28:339-347.
65. Nieddu M, Boatto G, Dessi G. Determination of 4-alkyl 2,5 dimethoxyamphetamine derivatives by capillary electrophoresis with mass spectrometry detection from urine samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852:578-581.
66. Nieddu M, Boatto G, Pirisi MA, et al. LC-MS analysis of trimethoxyamphetamine designer drugs (TMA series) from urine samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867:126-130.
67. Marais AA, Laurens JB. Rapid GC-MS confirmation of amphetamines in urine by extractive acylation. Forensic Sci Int. 2009;183:78-86.
68. Kamata HT, Shima N, Zaitsu K, et al.Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica. 2006;36:709-723.
69. Springer D, Peters FT, Fritschi G, et al. Studies on the metabolism and toxicological detection of the new designer drug 4#-methyl- alphapyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;773:25-33. (Pubitemid 34518267)
70. Springer D, Peters FT, Fritschi G, et al. New designer drug 4#-methylalpha- pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;789:79-91. (Pubitemid 36513789)
71. Springer D, Fritschi G, Maurer HH. Metabolism and toxicological detection of the new designer drug 4#-methoxy-a-pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;793:331-342. (Pubitemid 37271973)
72. Springer D, Fritschi G, Maurer HH. Metabolism and toxicological detection of the new designer drug 3#,4#-methylenedioxy-alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;793: 377-388. (Pubitemid 37271978)
73. Springer D, Fritschi G, Maurer HH. Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4#methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;796:253-266. (Pubitemid 37329670)
74. Peters FT, Meyer MR, Fritschi G, et al. Studies on the metabolism and toxicological detection of the new designer drug 4#-methyl- alphapyrrolidinobutyrophenone (MPBP) in urine using gas chromatographymass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;824:81-91.
75. Auwarter V, Dresen S,WeinmannW, et al.-Spice- and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009; 44:832-837.